PATH-03. Clinically Tractable Outcome Prediction of Group 3/4 Medulloblastoma Based on TPD52 Immunohistochemistry: a Multicohort Study

BACKGROUND: International consensus and the 2021 WHO classification recognize eight molecular subgroups among Group 3/4 medulloblastoma (representing ~60% of medulloblastoma). However, very few clinical centers worldwide possess the technical capabilities to determine DNA-methylation patterns or oth...

Descripción completa

Detalles Bibliográficos
Autores principales: Delaidelli, Alberto, Dunham, Christopher, Santi, Mariarita, Negri, Gian Luca, Triscott, Joanna, Zheludkova, Olga, Golanov, Andrey, Ryzhova, Marina, Okonechnikov, Konstantin, Schrimpf, Daniel, Stichel, Damian, Ellison, David, von Deimling, Andreas, Kool, Marcel, Pfister, Stefan, Ramaswamy, Vijay, Taylor, Michael, Korshunov, Andrey, Sorensen, Poul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Pathology/Classification
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164902/
http://dx.doi.org/10.1093/neuonc/noac079.587

Ejemplares similares

Ejemplares similares